PMID- 11377928
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20181130
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 25
IP  - 1
DP  - 2001 Jul
TI  - Tyrosine augments acute clozapine- but not haloperidol-induced dopamine release 
      in the medial prefrontal cortex of the rat: an in vivo microdialysis study.
PG  - 149-56
AB  - Tyrosine availability can influence dopamine (DA) synthesis in highly 
      electrophysiologically active DAergic neurons, such as those innervating the 
      medial prefrontal cortex (MPFC). Whether tyrosine concentrations can also affect 
      MPFC extracellular DA concentrations, measured in vivo, is not known. Since 
      clozapine preferentially activates mesocortical DA neurons, we posited that 
      tyrosine administration to a clozapine-pretreated rat would enhance the 
      clozapine-induced augmentation of MPFC extracellular DA concentrations. Tyrosine 
      alone (25-50mg/kg IP) did not affect mesocortical or striatal extracellular DA 
      concentrations measured by in vivo microdialysis. Given 30 minutes after 
      clozapine (10 mg/kg), tyrosine (50 mg/kg) significantly prolonged the 
      clozapine-induced increase in MPFC extracellular DA concentrations but had no 
      effect in the striatum. In contrast, tyrosine (50 mg/kg) significantly prolonged 
      the haloperidol (1 mg/kg) induced increase in striatal extracellular DA 
      concentrations but had no effect in the MPFC. These data constitute the first in 
      vivo evidence that administration of tyrosine can selectively potentiate the 
      clozapine-evoked increase in mesocortical extracellular DA concentrations.
FAU - Jaskiw, G E
AU  - Jaskiw GE
AD  - Veterans Affairs Medical Center, Cleveland, OH 44141, USA. gxj5@po.cwru.edu
FAU - Collins, K A
AU  - Collins KA
FAU - Pehek, E A
AU  - Pehek EA
FAU - Yamamoto, B K
AU  - Yamamoto BK
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Drug Combinations)
RN  - 42HK56048U (Tyrosine)
RN  - J60AR2IKIC (Clozapine)
RN  - J6292F8L3D (Haloperidol)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/*pharmacology
MH  - Clozapine/*pharmacology
MH  - Dopamine/*biosynthesis
MH  - Dopamine Antagonists/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Drug Interactions/physiology
MH  - Extracellular Space/drug effects/metabolism
MH  - Haloperidol/*pharmacology
MH  - Male
MH  - Microdialysis
MH  - Neostriatum/drug effects/metabolism
MH  - Neural Pathways/drug effects/metabolism
MH  - Neurons/drug effects/metabolism
MH  - Prefrontal Cortex/*drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Substantia Nigra/drug effects/metabolism
MH  - Time Factors
MH  - Tyrosine/metabolism/*pharmacology
EDAT- 2001/05/30 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/05/30 10:00
PHST- 2001/05/30 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/05/30 10:00 [entrez]
AID - S0893133X01002202 [pii]
AID - 10.1016/S0893-133X(01)00220-2 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2001 Jul;25(1):149-56. doi: 
      10.1016/S0893-133X(01)00220-2.